A new targeted pill for advanced pancreatic cancer has dramatically extended survival in a major clinical trial, offering a potential breakthrough for one of the deadliest forms of cancer. The drug, daraxonrasib, nearly doubled the typical survival time compared to standard chemotherapy.
In the Phase 3 trial involving patients whose cancer had progressed after initial treatment, those taking the daily pill lived a median of 13.2 months, compared to 6.7 months for those on chemotherapy. This represents a 6.5-month increase and a 60% reduction in the risk of death. The company reported that the drug met all primary and secondary goals of the study. "These are dramatic, practice-changing outcomes," said the company's CEO, who noted no drug has previously shown a survival benefit greater than one year in a late-stage pancreatic cancer trial.
Daraxonrasib works by broadly targeting RAS mutations, faulty genes that drive tumor growth and are found in roughly 90% of pancreatic cancer cases. This approach marks a significant shift away from exclusively using intravenous chemotherapy. Oncologists involved in the research described the data as transformational, noting that past successful trials often extended life by only weeks or a few months. The drug's safety profile was deemed manageable, with rash being a known side effect that clinicians report becoming more adept at controlling.
The company plans to soon seek U.S. regulatory approval using a fast-track process, aiming to bring the drug to market for second-line treatment within months. A separate Phase 3 trial is already underway to evaluate daraxonrasib in newly diagnosed patients. Researchers are optimistic the pill could become a foundational therapy used alone or in combination with other drugs, opening a new era of targeted treatment for a disease with a five-year survival rate of just 13%.
With full trial results set for presentation at a future medical meeting, the focus is now on preparing for a potential approval and launch. The compelling data has ignited hope that targeting RAS mutations could yield meaningful benefits for patients facing this aggressive cancer and other difficult-to-treat diseases.